BEVERLY HILLS, Calif.,
Aug. 6, 2021 /PRNewswire/ -- GT
Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a
clinical stage immuno-oncology company focused on developing
innovative therapeutics based on the Company's proprietary natural
killer (NK) cell engager (TriKE™) protein biologic technology
platform, today announced that the management team will host a
conference call to discuss second quarter 2021 financial results
and general business updates on August 13,
2021 at 8:30 a.m. EST.
To join the call:
- U.S. callers should dial 1-877-870-4263 and international
callers should dial 1-412-317-0790.
- All participants should ask to be connected to the GT Biopharma
conference call.
The call will be available by visiting the "Presentations" page
in the "News & Media" section of GT Biopharma's website at
www.gtbiopharma.com/news-media/presentations. A replay of the call
will be archived for 30 days following the presentation.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company
focused on the development and commercialization of immuno-oncology
therapeutic products based on our proprietary TriKE™ NK cell
engager platform. Our TriKE™ platform is designed to harness and
enhance the cancer killing abilities of a patient's immune system's
natural killer cells (NK cells). GT Biopharma has an exclusive
worldwide license agreement with the University of Minnesota to further develop and
commercialize therapies using TriKE™ technology. For more
information, please visit gtbiopharma.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
that involve risks, uncertainties and assumptions that are
difficult to predict, including statements regarding the potential
acquisition, the likelihood of closing the potential transaction,
our clinical focus, and our current and proposed trials. Words
and expressions reflecting optimism, satisfaction or disappointment
with current prospects, as well as words such as "believes",
"hopes", "intends", "estimates", "expects", "projects", "plans",
"anticipates" and variations thereof, or the use of future tense,
identify forward-looking statements, but their absence does not
mean that a statement is not forward-looking. Our
forward-looking statements are not a guarantee of performance, and
actual results could differ materially from those contained in or
expressed by such statements. In evaluating all such statements, we
urge you to specifically consider the various risk factors
identified in our Form 10-K for the fiscal year
ended December 31, 2020, in the section titled "Risk
Factors" in Part I, Item 1A, filed with the Securities and
Exchange Commission (the "SEC") on April 16,
2021 any of which could cause actual results to differ
materially from those indicated by our forward-looking
statements.
Our forward-looking statements reflect our current views with
respect to future events and are based on currently available
financial, economic, scientific, and competitive data and
information on current business plans. You should not place undue
reliance on our forward-looking statements, which are subject to
risks and uncertainties relating to, among other
things: (i) the sufficiency of our cash position and our
ongoing ability to raise additional capital to fund our operations,
(ii) our ability to complete our contemplated clinical trials,
or to meet the FDA's requirements with respect to safety
and efficacy, (iii) our ability to identify patients to enroll in
our clinical trials in a timely fashion, (iv) our ability to
achieve approval of a marketable product, (v) design,
implementation and conduct of clinical trials, (vii) the
results of our clinical trials, including the possibility of
unfavorable clinical trial results, (vii) the market for, and
marketability of, any product that is approved, (viii) the
existence or development of treatments that are viewed by medical
professionals or patients as superior to our products,
(ix) regulatory initiatives, compliance with governmental
regulations and the regulatory approval process, and social
conditions, and (x) various other matters, many of which are
beyond our control. Should one or more of these risks or
uncertainties develop, or should underlying assumptions prove to be
incorrect, actual results may vary materially and adversely from
those anticipated, believed, estimated, or otherwise indicated by
our forward-looking statements.
We intend that all forward-looking statements made in this press
release will be subject to the safe harbor protection of the
federal securities laws pursuant to Section 27A of the
Securities Act, to the extent applicable. Except as required
by law, we do not undertake any responsibility to update these
forward-looking statements to take into account events or
circumstances that occur after the date of this press release.
Additionally, we do not undertake any responsibility to update you
on the occurrence of any unanticipated events which may cause
actual results to differ from those expressed or implied by these
forward-looking statements.
Contact:
Institutional Investors:
Brendan Payne
Stern Investor Relations, Inc.
brendan.payne@sternir.com
212-362-1200
Investor & Media Relations:
David Castaneda
David@gtbiopharma.com
414-351-9758
Logo -
https://mma.prnewswire.com/media/1483265/GTBP_SmallLogo_Logo.jpg